Michael Mauro

20PUBLICATIONS
78CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiologically active moleculesCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Dec 02, 2025
How I treat advanced phases of CML.

Michael J Mauro

|Oct 07, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Ehab Atallah, Michael S Broder, Onyee Chan

|Jul 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross

|May 07, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro, Yosuke Minami, Andreas Hochhaus

|Apr 09, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.

Jorge E Cortes, Fabian Lang, Delphine Rea

|Apr 09, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.

Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes

Pageof 4

Frequent Collaborators

13 joint publications

Jorge E Cortes

9 joint publications

Jane F Apperley

9 joint publications

Andreas Hochhaus

7 joint publications

Koji Sasaki